BC
NVAX icon

Bridgefront Capital’s Novavax NVAX Stock Holding History

Bridgefront Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Sell
13,410
-73,508
-85% -$659K 0.03% 476
2026
Q1 		$708K Buy
+86,918
New +$788K 0.18% 195
2025
Q4 		– Sell
-16,788
Closed -$146K – 699
2025
Q3 		$146K Sell
16,788
-20,069
-54% -$156K 0.04% 544
2025
Q2 		$232K Buy
+36,857
New +$244K 0.06% 509
2023
Q1 		– Sell
-10,573
Closed -$109K – 533
2022
Q4 		$109K Buy
+10,573
New +$187K 0.08% 333
2022
Q1 		– Sell
-1,403
Closed -$201K – 380
2021
Q4 		$201K Buy
+1,403
New +$241K 0.2% 246
2021
Q3 		– Sell
-1,412
Closed -$300K – 578
2021
Q2 		$300K Buy
+1,412
New +$259K 0.11% 343

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Bridgefront Capital's NVAX Position: Q2 2026 in Review

Bridgefront Capital reduced its Novavax (NVAX) stake by 85% in Q2 2026, selling an estimated $659K and leaving 13,410 shares worth $126K. The position accounts for 0.03% of the portfolio, ranked #476.

Bridgefront Capital first reported a position in NVAX in Q2 2021 and has held it in 7 quarters since. The position peaked at $708K in Q1 2026. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Bridgefront Capital held 13,410 shares of Novavax worth $126K as of Q2 2026.
  • Bridgefront Capital sold 73,508 Novavax shares in Q2 2026, an estimated $659K.
  • Novavax made up 0.03% of Bridgefront Capital's portfolio in Q2 2026, its #476 holding.
  • Bridgefront Capital first reported a position in Novavax in Q2 2021 and has held it in 7 quarters since.
  • Bridgefront Capital's Novavax position peaked at $708K in Q1 2026.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.